Anticoagulant treatment during pregnancy: An update

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue SUPPL. 1, 1998, Pages 55-62

  Dizon Townson, Donna ^a   Ware Branch, D ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulation; Heparin; Pregnancy; Thrombophilia; Warfarin

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; DRUG CHOICE; FEMALE; HEPARINIZATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT PLANNING;

ANTICOAGULANTS; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; VENOUS THROMBOSIS; WARFARIN;

EID: 0031792026     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Koonin LM, MacKay AP, Berg CJ, Atrash HK, Smith JC. Pregnancy-related mortality surveillance-United States, 19871990. Morbidity Mortality Weekly Rep 1997:46:17-36
2. Pulmonary disorders. In: Cunningham G, MacDonald P, Gant N, Leveno K, Gilstrap L, Hankins G, Clark S (eds). Williams Obstetrics, 20th ed. Norwalk, CT: Appleton & Lange; 1997:1112
3. De Swiet M, Fidler J, Howell R, et al. Thromboembolism in pregnancy. In: Jewell D, ed. Advanced Medicine. London: Pitman Medical; 1981:309-317
4. Rutherford S, Montoro M, McGehee W, et al. Thromboembolic disease associated with pregnancy: An 11-year review. Am J Obstet Gynecol 1991 ; 164 (Suppl):286 (Abstr.)
5. Dixon JE. Pregnancies complicated by previous thromboembolic disease. BrJ HospMed 1987;37:449-52
6. Bergqvist A, Bergqvist D, Hallbook T. Deep-vein thrombosis during pregnancy. A prospective study. Acta Obstet Gynaecol Scand I983;62:443-44S
7. ACOG Educational Bulletin. Thromboembolism in Pregnancy. Number 234 March 1997
8. Toglia MR, Nolan TE. Venous thromboembolism during pregnancy: A current review of diagnosis and management. Obstet Gynecol Surv 1996:52:60-72
9. Toglia MR, Weng JG. Venous thromoboembolism during pregnancy. N Engl J Med I996;335:108-114
10. Coumarin derivatives. In: Briggs GG, Freeman RK, Yaffe SJ (eds). Drugs in Pregnancy and Lactation, 4th ed. Baltimore: Williams and Wilkins; 1994:223-229
11. DiSaia PJ. Pregnancy and delivery of a patient with a Starr-Edwards mitral valve prosthesis. Report of a case. Obstet Gynecol 1966:28:489-490
12. Franco B, Meroni G, Parent! G, et al. A cluster of sulfatase genes on Xp22.3: Mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. Cell 1995;81:1525
13. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980;68:122- 140
14. Todd ME, Thompson JH Jr, Bowie EJW, Owen CA Jr. Changes in blood coagulation during pregnancy. Mayo Clin Proc 1965; 40:370-383
15. Nilsson IM, Kullander S. Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynaecol Scand 1967;46:273285
16. National Institutes of Health Consensus Development Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986:256:744-749
17. Tengborn L, Bergqvist D, Matzsch T, Bergqvist A, Hedner U. Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis? Am J Obstet Gynecol 1989:160:90-94
18. Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. Br Med J 1974:1:215-217
19. Bertina RM. Introduction: Hypercoagulable states. Semin Haematol 1997:34:167-169
20. Zoller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-1538
21. Bertina RM, Koeleman BPC, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994:369:64-67
22. Dahlbäck B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994:24:139-151
23. Dizon-Townson D, Nelson L, Easton K, Ward K. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175:902-905
24. Hallak M, Senderowicz J, Cassel A, et al. Activated protein C resistance (Factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997; 176:889-893
25. Dizon-Townson D, Nelson LM, Jang H, Varner MW, Ward K. The incidence of the Factor V Leiden mutation in obstetrical population and its relation to deep-vein thrombosis. Am J Obstet Gynecol 1997;176:883-886
26. Conard J, Horellou MH, Van Dreden P, et al. Thrombosis and pregnancy in congenital deficiencies in ATIII, protein C or protein S: A study of 78 women. Thromb Haemostas 1990;63: 319-320
27. Pabinger I, Kyrie PA, Heistingcr M, et al. The risk of thromboembolism in symptomatic patients with protein C and Protein S deficiency: A prospective cohort study. Thromb Haemostas 1994:71:441-445
28. Hellgren M, Hagnevik K, Robbe H, et al. Severe acquired antithrombin III deficiency in relation to hepatic and renal insufficiency and intrauterine fetal death late in pregnancy. Gynecol Obstet Invest (FYA) 1983:16:107-118
29. Winter JH, Fenech A, Ridley W, et al. Familial antithrombin III deficiency. Q J Med 1982:51:373-395
30. Brandt P, Stenbjerg S. Subcutaneous heparin for thrombosis in pregnant women with hereditary antithrombin deficiency. Lancet 1979; 1:100-101
31. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience. Obstet Gynecol 1992:80:614-620
32. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: A collaborative randomized trial comparing prednisone to low-dose heparin treatment. Am J Obstet Gynecol 1992; 166: 1318-1327
33. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose heparin is superior to low-dose aspirin. Am J Obstet Gynecol 1995:174:1584-1589
34. Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol (DFA) 1996;14:131-136
35. Bais J, Pel M, von dem Borne A, van der Lelie H. Pregnancy and paroxysmal nocturnal hemoglobinuria. Eur J Obstet Gynecol ReprodBiol 1994:53:211-214
36. Imai A, Takagi H, Kawabata I, Sumi H, Shiraki S, Tamaya T. Successful pregnancy in a patient with paroxysmal nocturnal hemoglobinuria. Arch Gynecol Obstet 1989:246:121-124
37. Solal-Celigny P, Tertian G, Frenandez H, et al. Pregnancy and paroxysmal nocturnal hemoglobinuria. Arch Intern Med 1988; 148:593-595
38. Greene MF, Frigoletto FD Jr, Claster S, Rosenthal D. Pregnancy and paroxysmal nocturnal hemoglobinuria: Report of a case and review of the literature. Obstet Gynecol Surv 1983;38: 591-596
39. Hurd WW, Miodovnik M, Stys Sj. Pregnancy associated with paroxysmal nocturnal hemoglobinuria. Obstet Gynecol 1982; 60:742-746
40. Iturbe-Alessio I, Fonesca MDC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986;315:1390-1393
41. Ben Ismail MB, Abid F, Trabelsi S, Taktak M, Fekih M. Cardiac valve prosthesis, anticoagulation and pregnancy. Br Heart J 1986:55:101-105
42. Levine HJ, Pauker SE, Salzman EW. Antithrombotic therapy in valvular heart disease. Chest 1986;89(Suppl 2):3S-45S
43. Chesboro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease. J Am Coll Cardiol 1986;8(6 SupplB):41B-56B
44. Caruso A, De Carolis S, Ferrazzani S, et al. Pregnancy outcome in women with cardiac valve prosthesis. Eur J Obstet Gynecol ReprodBiol 1994;54:L7-81\
45. Barbour LA, Smith JM, Marlar RA. Heparin levels to guide thromboembolism prophylaxis during pregnancy. Am J Obstet Gynecol 1995:173:1869-1873
46. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1995;108:305S-311S
47. Ad hoc Committee of the Working Group on Valvular Heart Disease, European Society of Cardiology: Guidelines for prevention of thromboembolic events in valvular heart disease. J Heart Valve Disease 1993:2:398-410
48. McKay DG, Merrill SJ, Weiner AE, Hertig AT, Reid DE. Pathologic anatomy of eclampsia, bilateral renal cortical necrosis, pituitary necrosis and other acute fatal complications of pregnancy and its possible relationship to the generalized Shwartzman phenomenon. Am J Obstet Gynecol 1953;66:507-539
49. McKay DG. Hématologie evidence of disseminated intravascular coagulation in eclampsia. Obstet Gynecol Surv 1972;27:399417
50. Page EW. On the pathogenesis of preeclampsia. Br J Obstet Gynaecol 1972:79:883-894
51. Vassali P, Morris RH, McCluskey RT. The pathogenic role of fibrin deposition in the glomerular lesions of toxemia of pregnancy. J Exp Med 1963;! 18:467-478
52. Arias F, Mancilla-Jimenez R. Hepatic fibrinogen deposits in preeclampsia. N Engl J Med 1976;295:578-582
53. Benirschke K, Kaufman P (eds). Pathology of the human placenta. New York: Springer-Verlag 1995:494-512
54. Dizon-Townson D, Meline L, Nelson L, Varner M, Ward K. Fetal carriers of the Factor V Leiden mutation are prone to miscarriage and placenta! infarction. Am J Obstet Gynecol 1997:177:402-405
55. Dizon-Townson D, Nelson L, Easton K, Ward K. The Factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175:902-905
56. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995:173:1042-1048
57. Lindoff C, Ingemarsson I, Martinsson G, et al. Preeclampsia is associated with a reduced response to activated protein C. Am J Obstet Gynecol 1997; 176:457-460
58. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol I989;161: 1200-1204
59. Saleh AA, Bottoms SF, Welch RA, et al. Preeclampsia, delivery, and the hemostatic system. Am J Obstet Gynecol 1987:157: 331-336
60. Frigoletto F. Diagnostic Imaging Ultrasound in Pregnancy. US Department of Health and Human Services, Public Health Service, National Institutes of Health, pub. No. 84667, 1986
61. Paz I, Gale R, Laor A, et al. The cognitive outcome of full-term small-for gestational-age infants at late adolescence. Obstet Gynecol 1995:85:452-156
62. Piper JM, Xenakis EMJ, McFarland M, et al. Do growth retarded premature infants have different rates of perinatal morbidity and mortality than appropriate-grown premature infants? Obstet Gynecol 1996:87:169-174
63. Redline RW. Placenta! pathology: A neglected link between basic disease mechanisms and untoward pregnancy outcome. Curr Opin Obstet Gynecol 1995;7:10-15
64. Redline RW, Pappin A. Fetal thrombotic vasculopathy: The clinical significance of extensive avascular villi. Hum Pathol 1995; 26:80-85
65. Laurini R, Laurin J, Marsal K. Placental histology and fetal blood flow in intrauterine growth retardation. Acta Obstet Gynaecol Scand 1994;73:529-534
66. Rayne SC, Kraus FT. Placental thrombi and other vascular lesions: Classification, morphology, and clinical correlations. Pathol Res Pract 1993:189:2-17
67. Rotmensch S, Liberati M, Mittelmann M, Ben-Rafael Z. Activated protein C resistance and adverse pregnancy outcome. Am J Obstet Gynecol 1997;177:170-173
68. Amer L, Kisiel W, Searles RP, Williams RC. Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. ThrombRes 1990;57:247-258
69. Rossi E, Gatti L, Guarneri D, et al. Functional protein S in women with lupus anticoagulant inhibitor. Thromb Res 1992; 65:253-262
70. DcWolf F, Carreras LO, Moerman P, et al. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant. Am J Obstet Gynecol 1982:142:829-834
71. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Hacmostas 1997;77:822-824
72. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996:348:913916
73. Dizon-Townson D, Kinney S, Branch DW, Ward K. The Factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997:34:217-223
74. Metz J, Kloss M, O'Malley CJ, et al. Prevalence of Factor V Leiden is not increased in women with recurrent miscarriage. Clin Appl Thromb Hemostas 1997:3:137-140
75. Rai, R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996;92:489-490
76. Brancazio LR, Ropcrti KA, Stierer R, Laifer SA. Pharmacokinctics and pharacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995; 173:1240-1245
77. Matzseh T, Bergqvist D, Bergqvist A, et al. 'No transplacental passage of standard heparin or an enzymatically depolymerized low-molecular-weight heparin. Blood Coag Fibrinolysis 1991;2:273-278
78. Forestier F, Sole Y, Aliach M, Alhene Gelas M, Daffos F. Absence of transplacental passage of Fragmin (Kabi) during the second and third trimesters of pregnancy. Thromb Haemostas 1992; 67:180-181
79. Melissari E, Parker CJ, Wilson N, et al. Use of low-molecularweight heparin in pregnancy. Thromb Haemostas 1992;68: 652-656
80. Henny CP, ten Cate H, ten Cale JW, et al. Thrombosis prophylaxis in an ATIII deficient pregnant woman: Application of a low-molecular-weight heparinoid. Thromb Haemostas 1986; 55:301 (Letter)